Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFNγ signaling defects.

Molecular cancer·2026
Same author

Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD.

European journal of cancer (Oxford, England : 1990)·2026
Same author

TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with <i>EGFR</i>-mutated locally advanced or metastatic non-small cell lung cancer.

Therapeutic advances in medical oncology·2026
Same author

Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancer.

Journal of neuro-oncology·2026

Related Experiment Video

Updated: Apr 3, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.5K

Lung Cancer Brain Metastases.

Sarah B Goldberg1, Joseph N Contessa, Sacit B Omay

  • 1From Yale School of Medicine, New Haven, CT.

Cancer Journal (Sudbury, Mass.)
|September 22, 2015
PubMed
Summary

Advances in lung cancer treatment, including systemic therapies, offer improved outcomes for brain metastases. Understanding disease characteristics guides personalized treatment for better survival and reduced toxicity.

More Related Videos

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

28.5K
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

8.3K

Related Experiment Videos

Last Updated: Apr 3, 2026

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

8.5K
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
07:43

Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis

Published on: February 8, 2017

28.5K
Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging
06:44

Modeling Brain Metastases Through Intracranial Injection and Magnetic Resonance Imaging

Published on: June 7, 2020

8.3K

Area of Science:

  • Neuro-oncology
  • Medical Oncology
  • Radiotherapy

Background:

  • Brain metastases are a frequent complication of lung cancer, leading to poor prognosis.
  • Treatment historically focused on local therapies with limited efficacy.
  • Recent advancements in CNS imaging, surgery, and radiation have improved patient outcomes.

Purpose of the Study:

  • To review current treatment strategies for lung cancer brain metastases.
  • To highlight the role of systemic therapies in managing intracranial disease.
  • To provide an update on surgical and radiotherapy techniques.

Main Methods:

  • Review of recent literature on lung cancer brain metastases.
  • Analysis of systemic therapy efficacy in the central nervous system.
  • Evaluation of advancements in local treatment modalities.

Main Results:

  • Systemic therapies (chemotherapy, targeted therapy, immunotherapy) show CNS activity.
  • Improved local treatments reduce toxicity and increase durability.
  • Personalized treatment selection based on disease burden and molecular profile is crucial.

Conclusions:

  • Integrated treatment approaches combining local and systemic therapies are essential.
  • Systemic therapies can delay or replace local treatment for select patients.
  • Further research is needed to optimize treatment sequencing and combination strategies.